Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 6/2019

01-12-2019 | Ulcerative Colitis | Case Report

Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance

Authors: Koichi Soga, Kenji Itani

Published in: Clinical Journal of Gastroenterology | Issue 6/2019

Login to get access

Abstract

A 47-year-old Japanese man was diagnosed with pancolitis-type ulcerative colitis. He was treated with mesalamine in a pH-dependent release form. On day 16 of administration, he was admitted because of fever and abdominal pain. We diagnosed his symptoms to be the side effects of mesalamine. Hyposensitization using unmodified and a time-dependent release form mesalamine was performed. On day 7 of mesalamine hyposensitization, a colonoscopy was performed. The patient presented with the same allergic symptoms 9 h after the administration of an oral sodium phosphate solution. Eventually, he was orally administered a course of salazosulfapyridine (SASP) at an initial dose of 2.5 mg/day, which was increased to 2000 mg/day. It is generally recognized that SASP intolerance is an indication to switch from SASP to mesalamine. The need to switch treatment from mesalamine to SASP is, therefore, rare because allergic reactions to mesalamine do not occur frequently. We report a very rare case which was presented with abdominal pain and myalgia because of intolerance to mesalamine in whom hyposensitization with and introduction of SASP were successful.
Literature
1.
go back to reference Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. J Pharmacol Exp Ther. 1972;181:555–62.PubMed Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. J Pharmacol Exp Ther. 1972;181:555–62.PubMed
2.
go back to reference Sturgeon JB, Bhatia P, Hermens D, et al. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology. 1995;108:1889–93.CrossRef Sturgeon JB, Bhatia P, Hermens D, et al. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology. 1995;108:1889–93.CrossRef
3.
go back to reference Bousseaden A, Ajana FZ, Essamri W, et al. Mesalamine enema-induced exacerbation of ulcerative colitis. Int J Colorectal Dis. 2009;24:1359–60.CrossRef Bousseaden A, Ajana FZ, Essamri W, et al. Mesalamine enema-induced exacerbation of ulcerative colitis. Int J Colorectal Dis. 2009;24:1359–60.CrossRef
4.
go back to reference Scribano ML. Adverse events of IBD therapies. Inflamm Bowel Dis. 2008;14(Suppl 2):S210–1.CrossRef Scribano ML. Adverse events of IBD therapies. Inflamm Bowel Dis. 2008;14(Suppl 2):S210–1.CrossRef
5.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625–9.CrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625–9.CrossRef
6.
go back to reference Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–9.CrossRef Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–9.CrossRef
7.
go back to reference Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am. 1992;21:643–58.PubMed Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am. 1992;21:643–58.PubMed
8.
go back to reference Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83:1062–70.PubMed Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83:1062–70.PubMed
9.
go back to reference Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3:893–903.PubMedPubMedCentral Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3:893–903.PubMedPubMedCentral
10.
go back to reference Rubin DT, Mikolajczyk A, Surma B. Measurement of luminal pH in patients with mildly to moderately active UC: a pilot study using SMARTpill pH. Gastroenterology. 2009;135:A349. Rubin DT, Mikolajczyk A, Surma B. Measurement of luminal pH in patients with mildly to moderately active UC: a pilot study using SMARTpill pH. Gastroenterology. 2009;135:A349.
11.
go back to reference Menees S, Higgins P, Korsnes S, Elta G. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007;13:12–8.CrossRef Menees S, Higgins P, Korsnes S, Elta G. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007;13:12–8.CrossRef
12.
go back to reference Schleiermacher D, Hoffmann JC. Pulmonary abnormalities in inflammatory bowel disease. J Crohns Colitis. 2007;1:61–9.CrossRef Schleiermacher D, Hoffmann JC. Pulmonary abnormalities in inflammatory bowel disease. J Crohns Colitis. 2007;1:61–9.CrossRef
13.
go back to reference Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103:1925–7.CrossRef Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103:1925–7.CrossRef
14.
go back to reference Fardy JM, Lloyd DA, Reynolds RPE. Adverse effects with oral 5-aminosalicylic acid. J Clin Gastroenterol. 1988;10:635–7.CrossRef Fardy JM, Lloyd DA, Reynolds RPE. Adverse effects with oral 5-aminosalicylic acid. J Clin Gastroenterol. 1988;10:635–7.CrossRef
15.
go back to reference Gonzalo MA, Alcalde MM, García JM, et al. Desensitization after fever induced by mesalazine. Allergy. 1999;54:1224–5.CrossRef Gonzalo MA, Alcalde MM, García JM, et al. Desensitization after fever induced by mesalazine. Allergy. 1999;54:1224–5.CrossRef
16.
go back to reference Varela S, Díez MS, Gonzalez C, et al. Oral desensitization to 5-ASA. Allergy. 2002;57:371–2.CrossRef Varela S, Díez MS, Gonzalez C, et al. Oral desensitization to 5-ASA. Allergy. 2002;57:371–2.CrossRef
17.
go back to reference Oustamanolakis P, Koutroubakis IE. New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. Inflamm Bowel Dis. 2011;17:E8–9.CrossRef Oustamanolakis P, Koutroubakis IE. New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. Inflamm Bowel Dis. 2011;17:E8–9.CrossRef
18.
go back to reference Korelitz BI, Present DH, Rubin PH, et al. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J Clin Gastroenterol. 1984;6:27–31.CrossRef Korelitz BI, Present DH, Rubin PH, et al. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J Clin Gastroenterol. 1984;6:27–31.CrossRef
19.
go back to reference Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.PubMed Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.PubMed
20.
go back to reference Wang Y, Parker CE, Feagan BG, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;5:000544. Wang Y, Parker CE, Feagan BG, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;5:000544.
Metadata
Title
Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance
Authors
Koichi Soga
Kenji Itani
Publication date
01-12-2019
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 6/2019
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-00985-9

Other articles of this Issue 6/2019

Clinical Journal of Gastroenterology 6/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.